Overcoming Tumor Resistance in Glioblastoma (IMAGE)
Caption
Glioblastomas -- the most common and aggressive brain tumors -- are known to recur and progress within short times from the diagnosis. Patients diagnosed with this type of cancer, and who undergo current standard treatment, have a median survival of 16 months. Researchers developed a new clinical approach to increase the efficiency of treatment that increased the median survival to 22 months -- bringing much needed hope to those affected by this aggressive disease.
Credit
McGill University Health Center
Usage Restrictions
None
License
Licensed content